

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Common Agenda					
Support global health initiatives by providing up-to-date information about current issues in drug quality and appropriate use					
Fine tune screening and testing protocol for medicine quality monitoring	A. Barojas	Harmonization team worked on finalizing "Guidelines to Establishing a Medicine Quality Monitoring Program" document and sent to select PQM staff for comments	Incorporated comments, finalized document, and sent it to USAID. PQM will implement this document and update it in 6-12 month cycles		Finalized document was translated to Spanish
Evaluate alternative screening technologies for the detection of substandard and counterfeit medicines	K. Chibwe & D. Bempong	The Ahura Raman hand-held device is being promoted by Ahura as a QC tool. PQM is working with Ahura to verify this claim	Ahura and PQM developed an experimental plan to evaluate Truscan as a QC tool	Procuring antimalarial samples to be used to evaluate Truscan (Raman handheld tool); evaluation should be complete in Q4	Ahura undertaking independent study for quality check claim. Ahura scheduled to provide instrument in FY11 Q1
Update and overhaul the DQI/PQM websites	M. Foster	Added PQM info to DQI landing page Designed PQM site and organization with USP-IT Added 13 new articles and 10 photos; updated 3 existing web pages and 2 AI reports; added or updated 3 resource materials	Continue to work with USP communications and IT groups to procure domain, organize website, create content and fix several broken links Added 6 new articles and 2 photos; updated 2 web pages and 1 AI report; added 2 resource materials	Continue to work with USP communications and IT groups to finalize content Created content for 7 landing pages, 3 new activities, and 23 descriptors; updated 9 activities and cross-referenced links to DQI site Created content and provided demographics for 23 countries and 2 initiatives Submitted 8 new articles and 5 photos; updated 2 AI reports and 1 page; added H1N1-2009 report and 1 resource	Met with USP communications and IT groups to learn reasons for delays on PQM website launch and discuss possible solutions Created content for 8 activities for PQM site Submitted 15 new articles and 16 photos; updated 2 AI and H1N1 reports; updated TB meds for EOIs; and added 1 resource
Update and promote the Matrix of Medicine Quality Reports Affecting USAID-assisted Countries	M. McGinnis	Added 23 new reports Received 4,662 web hits Sent drug quality alerts to MRAs in relevant USAID-	Added 30 new reports Received 6,505 web hits Distributed at a Briefing for the House of Rep Foreign	Added 28 new reports Received 2,378 web hits Distributed at Global Health Council annual conference	Added 28 new reports Received 5,170 web hits Distributed to USAID/Russia delegation

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Finalize e-learning modules on medicines quality assurance	A. Barojas	priority countries In progress	Affairs Subcmte on Africa Updated outline; module content was sent to USAID for review	Awaiting USAID comments on latest submission	Awaiting USAID comments on latest submission
Stimulate the interest of stakeholders in medicine quality					
Attend and present at conferences advocating public health issues	P. Lukulay		P. Lukulay made a presentation titled "The hunt for counterfeit/ substandard medicines" February 24 in Florida at the 5 th Global Forum on Pharmaceutical Anticounterfeiting	Abstracts for two presentations on anticounterfeiting were prepared and submitted; the presentations will be given in November in New Orleans at the AAPS conference	S. Phanouvong presented an overview of the PQM program for pharmacy students visiting USP in August P. Lukulay gave a presentation titled "Strengthening Developing Countries to Detect Counterfeit and Substandard Medicines" at the Nigerian Pharmaceutical Association meeting in Dallas, TX in September
Tuberculosis (TB) P Lukulay					
Reduce the spread of MDR- and XDR-TB through better access to second-line treatment					
Continue to provide technical assistance to manufacturers of second-line TB medicines identified in FY 09 seeking to obtain WHO pre-qualification		Evaluated UNILAB (Philippines) manufacturing facilities for Levofloxacin and Amikacin; briefed them on dossier requirements Continued to review dossier from Sintez (Russia) for Levofloxacin manufacturing	Reviewed Dossiers from: Sintez (Russia) Levofloxacin 500mg tablets and Kanamycin powder for injection; Unilab (Philippines) Levofloxacin 700mg tablets; Svicera (India) Capreomycin powder for injection, Ethionamide 250mg tablets, Levofloxacin 250mg tablets and Cycloserine 250mg tablets Sent comments to manufacturers to implement correctives actions	Continue TA to Sintez, Unilab, and Svicera toward prequal. PQM will visit Svicera in Q4. Svicera submitted Capreomycin powder for injection, Ethionamide 250mg tablets, Levofloxacin 250mg tablets, and Cycloserine 250mg tablets dossiers to WHO Prequal in June 2010.	Visited Svicera for GMP assessment. Facility is in compliance with WHO requirements. Continue to work with Sintez Kanamycin dossier reviews. Sintez to submit the dossiers by December 2010 Traveled to Brazil in September to assess two 2nd line anti-TB manufacturers (Laboratorio Farmaceutico da Marinha

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
					and Farmanguinhos). Visited Cipla (India) to discuss 2nd line anti-TB medicines TA. Cipla to request PQM TA for Capreomycin and Ethionamide prequalification next FY. Visited Lupin (India) to discuss future products TA. Lupin to request PQM TA for Prothionamide and Ethionamide next FY.
Liaise with GDF and WHO on behalf of USAID, especially with WHO Assessors and Scientific Working Group		Four PQM staff traveled to Geneva and met with the WHO Prequalification team to foster cooperation and collaboration between PreQ and PQM. Both WHO and PQM pledged to cooperate more closely.	Two PQM staff participated in a WHO dossier assessment workshop in Copenhagen, at the invitation of the WHO Prequalification team. PQM conducted a workshop for second-line TB manufacturers in Sao Paulo, Brazil. Staff from WHO and GDF briefed the participants on requirements for prequalification. One company has committed to requesting PQM TA.	PQM conducted workshops in collaboration with GDF and the WHO prequalification program in Russia at the Man and Drugs conference and in Brazil to inform manufacturers about the prequalification process.	PQM continuing to work closely with GDF to facilitate the prequalification of 2 nd line TB medicines and hold regular teleconferences to plan assistance to manufacturers
Develop literature on PQM technical assistance for manufacturers and update PQM website with current information		A 1-pg flyer was prepared to describe PQM technical assistance to 2 nd line anti-TB manufacturers		Flyer updated to reflect new products eligible for prequalification	Fliers have been printed and used by PQM staff when they travel
Finalize the development of two pharmacopeial monographs for Prothionamide and		Global Pharma Health Fund contacted to develop the Minilab methods and invoice is being prepared.	Minilab methods for levofloxacin, moxifloxacin, and prothionamide were completed	Three additional 2 nd line anti-TB medicines identified as candidates for inclusion in the Minilab portfolio	Development of Minilab methods underway

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Levofloxacin and develop Minilab methods for two additional second line anti TB medicines					
Hire full-time GMP specialist to focus on technical assistance for SLD manufacturers		Lead candidates identified; interviewed 3 candidates	Search opened for new candidate	GMP specialist hired	GMP staff onboard
Collaborate with GDF to identify and provide technical assistance to additional SLD manufacturers				Additional manufacturers identified in Russia and Brazil	Additional manufacturers being contacted
Conduct operational research to assess the quality and availability of second-line anti-TB medicines in the public and private sector in select countries		One country identified in collaboration with GDF- (Ethiopia) as it is a high burden TB country.	Preliminary survey completed in Ethiopia shows that 4% of private pharmacies sell SLD without prescription	A survey of pharmacies done in Ghana found 2% of carry 2 nd line anti-TB medicines and dispense without prescriptions	Research reports produced
Malaria K. Chibwe					
Promote cooperation on drug quality issues through a network of African medicine quality control laboratories (NAMCOL)					
Disseminate QAMSA report and review lessons learned			Press release issued in February WebEx held in March to promote QAMSA report; attended by 43 participants		Feedback on QAMSA completed
Promote cooperation on drug quality issues through NAMCOL		Letters seeking formal sign-off on NAMCOL network sent to directors of national QC labs of Ethiopia, Mali, Ghana, Senegal, and Uganda First proficiency testing using quinine sulfate	Virtual forum concept developed and awaiting launch Sourcing for quinine sulfate identified in India. Two sign-offs on NAMCOL still outstanding	Quinine sulfate sourced, distributed to NAMCOL members for testing Kenya became the newest member of NAMCOL First proficiency training scheduled for Q4	NAMCOL Annual Meeting and training for senior scientists held in Bamako, Mali September 2010. All six member countries represented. FY11 work plan proposal tabled Virtual Forum design and

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
		awaiting final approval for NAMCOL members			hosting awarded to Small Valley Consulting; completion by FY11 Q1
Create reference standards system for Africa			Ongoing	Audited the Kenya lab (WHO prequalified lab) Presented at the Kenya Pharmaceutical Society Meeting in Mombasa May 2010 on the Reference Standards System for Africa	Progress presented at Annual NAMCOL meeting September 2010 USP may provide way-forward for this activity in FY11
Maternal Health and Child Survival		E Toledo			
Prevent and treat childhood diarrheal illness					
Assist Shelys Pharmaceutical, Tanzania, in WHO prequalification process		Provided TA to Shelys Pharmaceutical (Tanzania) on WHO prequal queries related to dossier submission	Shelys (Tanzania) was inspected by WHO Prequal in February with non-critical observations. PQM is providing TA to address WHO GMP-related queries.	PQM visited Shelys in August to review WHO queries. Shelys is investing \$200,000 to bring facilities to compliance as part of GMP corrective actions. PQM performed Dissolution profile for zinc tablets as par of dossier requirements on Biowaiver. PQM continues with TA support toward prequalification.	PQM continue support to Shelys, Dossier queries have been addressed with few comments from WHO; Biowaiver application finished and sent to WHO along with taste study report. Shelys to request WHO GMP re-inspection by January 2010
Assist DJPL, Nepal, in obtaining WHO prequalification of zinc product		Provided TA to DJPL Pharmaceutical (Nepal) on dossier prep prior to submission to WHO Prequalification Program	DJPL submitted dossier to WHO January 2010.	DJPL is working with WHO queries related to dossier. PQM continues with TA toward prequalification.	Visit DJPL scheduled for October, to assess new GMP facilities and assess WHO queries for zinc tablets 10mg and 20mg
Continue technical assistance to Zenufa, Tanzania, to achieve certification of compliance with Tanzanian cGMP standards				Zenufa agreed with Nutriset to manufacture Zinc tablets in Tanzania. Zenufa will prepare a dossier for Zinc Sulfate Syrup. PQM continues with TA support toward prequalification.	
Provide QC/GMP technical assistance to additional zinc manufacturers in				Traveled to Indonesia to provide TA in dossier compilation to Kalbe Pharmaceutical toward WHO	Kalbe is compiling zinc tablet dossier and requested dissolution studv support. PQM

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Indonesia, India, or other priority countries				prequal. During the visit, Kalbe and AED Indonesia requested TA in dossier compilation and GMP for Zinc Sulfate.	advised Kalbe to finish compiling zinc dossier first and request API quality information from the supplier
Develop one pharmacopeial monograph on zinc acetate formulations				Zinc acetate syrup monograph donated by Cipla (India) was submitted and is in the pipeline	Visited Cipla in August to discuss zinc acetate monograph, analytical method validation. Cipla to provide validation report by FY11 Q1
Conduct medicine quality testing of zinc samples sent by UNICEF and other partners		Tested one zinc sulfate sample from UNICEF		Tested zinc samples for Nutriset in France and Shelys in Tanzania	No requests for testing
Improve newborn health outcomes					
Conduct GMP assessment of chlorhexidine manufacturers for global and local supply		Conducted GMP assessment on Lomus Pharmaceutical (Nepal) for chlorhexidine manufacturing; briefed them on zinc dossier preparation	Provided TA to Lomus on dossier prep prior to submission to WHO	Visit to Lomus planned for Q4 or FY11 Q1	Visit to Lomus planned for FY11 Q1
Develop a pharmacopeial monograph for chlorhexidine gel formulation				Activity is pending the results of suitability studies from Bangladesh	Activity is pending the results of suitability studies from Bangladesh
SUB-SAHARAN AFRICA					
Benin	M. Hajjou				
Provide basic supplies necessary to conduct training			Supplies procured	Supplies delivered	
Conduct training in GPL and dissolution to strengthen NQCL capabilities			Planned for Q3	Training in GLP and Fourier Transform Infrared (FTIR) spectroscopy provided to 7 staff of NQCL	Training in dissolution discussed with the lab and planned in FY11
Evaluate and monitor NQCL staff conducting dissolution testing of selected antimalarials;				Each participant in the training will run an ID test on a sample using FTIR and provide a report to	The evaluation of the training will be conducted in-country in FY11 Q2

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
review testing report drafted by NQCL, provide recommendations				PQM for review.	
Ethiopia	A. Smine				
PEPFAR					
Strengthen DACA quality control lab capacities with training, equipment, planning, and move to new facility		<ul style="list-style-type: none"> – Trained 27 DACA analysts on HPLC and dissolution in Oct 2009 – Finalized key SOPs – One PQM staff member is assisting the lab for first two-week rotation in Jan 2010 – Prepared to purchase a power generator for new QC lab – Provided specialized lab design through PQM-hired consultant 	<ul style="list-style-type: none"> – Made a list of all lab equipment – Finalized 13 SOPs and trained all lab staff on quality systems and basics of GC – Purchased a power generator for DACA's new facility – Signed MOU with DACA and Regional Health Bureau of Oromia – Made a database of all lab chemicals – Hired an architect to make ISO17025 design for the new lab – Two PQM staff did lab rotations in January and March 	<ul style="list-style-type: none"> – Trained the DACA lab staff on quality systems and analytical methods – The implementation plan was revised by USP consultant and PQM staff – Specialized consultant completed the design draft of new DACA QC lab facility – Training for DACA lab on IR and QS planned for early Q4 	<ul style="list-style-type: none"> – Training on IR and GC along with HPLC troubleshooting was conducted – Recommendations for design and fitting of new lab were implemented – Quality System continues to be established; more SOPs were added – Staff from DACA were sent abroad to learn from others MRAs – Process for registering USP/PQM in Ethiopia is nearly complete – Three staff for the Addis office were hired and space rented – Lab equipment serviced by a contractor – PQM office rented and work is on-going for partitioning the office
Strengthen DACA drug registration through assessment, training, and TA		Planned for Q2-Q3	<ul style="list-style-type: none"> – Drug registration assessment done – Training on drug registration with WHO will be done in April 	Conducted a training for DACA on GMP and drug registration, in collaboration with WHO	Registration conducted but computer-based registration has not yet taken place. PQM is evaluating options
Establish medicine quality monitoring program for ARVs and antimalarials		Planned for Q2-Q3	Planned for Q3	Part of the sampling has been done; MQM plan will be finalized early Q4	DACA inspectors collected samples of ARVs from three sites; the protocol will be reviewed and updated
Promote enforcement actions by DACA		Pending data	Pending data	Pending data	Pending data
PMI					

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Establish Medicine Quality Monitoring program in Oromia region		<ul style="list-style-type: none"> – New teams established for sentinel sites – Equipment and supplies for sentinel sites purchased and received – Refresher training conducted in Jan 2010 – First round of 2010 will begin in Q2 	<ul style="list-style-type: none"> – Equipment and supplies delivered for sentinel sites – Trained 15 staff on basic tests – Finalized the FY09 data report – First round will start in April 	<ul style="list-style-type: none"> – Completed the sampling and basic tests at five sentinel sites in Oromia region. Confirmatory tests are ongoing in DACA lab. 	<ul style="list-style-type: none"> – Completed the first round of confirmatory testing – QC staff are working on the final report
Expand MQM to two sites outside Oromia region (depending upon success of first round).		Planned only if first round is well done	Pending the results of the first round, planned for Q4	Pending the results of the first round, planned for Q4	Not possible to accomplish this year; will take place in FY11
Disseminate MQM data, raise awareness and promote enforcement actions		FY09 data shared with USAID and PMI partners	Pending FY10 data	Pending FY10 data	Pending FY10 data
Ghana	P. Lukulay				
Monitor medicine quality at 5 selected sentinel sites		<ul style="list-style-type: none"> – Purchased and sent necessary Minilab equipment – First round planned for Q2 	Testing round to begin soon	Minilab testing completed and samples undergoing confirmatory testing	Confirmatory testing completed and three counterfeits identified (Metakelfin, Quinine Sulfate and Artesunate); FDB and UAP will issue press releases
Increase awareness about drug quality issues and promote enforcement actions by FDB		P. Lukulay met with new CEO of FDB and obtained commitment for enforcement action			Working with PQM consultants to raise awareness at grass roots levels
Provide TA toward ISO accreditation					Held initial meetings with community groups
					Laboratory assessment on-going
Kenya	L. El Hadri				
Conduct a comprehensive assessment of the capability of PPB to test the quality of antimalarials		Conducted in-country assessment; activity completed			

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Establish post-marketing surveillance program with Minilab training in testing the quality of antimalarials		<ul style="list-style-type: none"> Developed MQM protocol for monitoring antimalarials Identified 5 sentinel sites Procured 3 Minilabs Provided supplies to conduct one round of MQM activities Replenished supplies for 2 existing Minilabs 	<ul style="list-style-type: none"> Trained 14 staff on Minilab basic tests Finalized and submitted MQM protocol to partners Provided budget to carry out first round of testing in 5 sites First round will begin in May 2010 	<ul style="list-style-type: none"> First round completed at sentinel site level 536 samples collected from 5 sentinel sites 26 samples failed Minilab basic tests; 94 were sent to NQCL for confirmatory testing, including some passed and doubtful samples 	<ul style="list-style-type: none"> 536 antimalarials collected, 66 not analyzed (Minilab methods not available) , 64 to be confirmed Minilab data revised and samples to be confirmed by NQCL validated Confirmatory testing will be performed by NQCL upon receiving funds from DOMC Selected antimalarial samples procured to develop Minilab TLC methods
Liberia	A. Smine				
Support development of LMRC legislation		<ul style="list-style-type: none"> Organized two-day workshop with local stakeholders Nov 2009 Finalized LMRA draft zero legislation 	Legislation passed the Ministry of Justice and is being finalized	Legislation is now at the President's office and will soon be sent to Parliament to be enacted	Legislation signed by parliament and president USP will issue a press release about the approval
Strengthen quality control of antimalarial medicines		<ul style="list-style-type: none"> Sent Minilab reference standards, supplies and sampling plan LMRC staff will conduct sampling in Q2 Testing planned for Q2 	<ul style="list-style-type: none"> Collected 300 antimalarials from Monrovia, Kataka, and Ganta PQM trained staff from LMRC, MOH, Board of Pharmacy, and MCP on basic tests PQM and trained staff tested 254 samples and drafted a report. Provided all RS for testing Purchased 2 air conditioners for LMRC Testing of samples will begin soon 	<ul style="list-style-type: none"> Testing completed; data was disseminated to all stakeholders Recommendations were made for LMRC to take quick actions based on the data 	<ul style="list-style-type: none"> Drug quality data produced by PQM was widely distributed PQM is discussing future activities with USAID/Liberia
Mali	M. Hajjou				
Strengthen the capacity of the medicine quality		Procured laboratory supplies		To strengthen LNS' capacity, training in FTIR	Karl Fischer titrator installed

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
control division of the LNS by helping plan QC testing, equip the lab, and provide TA on insecticides				was provided to nine staff from the lab. Small lab supplies were provided for the training.	Reviewed procedure for testing insecticides from treated nets. Testing of insecticides is ongoing.
Establish a medicine quality monitoring/ postmarketing surveillance program with training, collecting and reporting of antimalarials		Procured Minilabs and laboratory supplies	Organized a training workshop to establish medicine quality monitoring at 8 sites; 21 participants were trained in basic tests and sampling procedures	Refresher training in basic tests was provided to the teams at the sentinel sites. Minilabs were installed and resources provided to conduct one round of sampling and testing	Sampling and testing of antimalarials completed at 4 sentinel sites. Results are being reviewed. Testing at the remaining sites to be completed FY11 Q1. At Gao, some pharmacists removed medicines that failed testing. Draft and review of the annual report will be done in FY11 Q1
Strengthen the pharmacovigilance program by facilitating training for a CNRP staff member and by providing reference books and technical assistance		Finalized and disseminated reporting form		Training for one CNRP staff is planned for Q4 at the Morocco Center for PV; Reference materials will also be sent in Q4	Reference materials procured and delivered to CNRP. One person from CNRP will receive training in Nov 2010.
Rwanda	A. Smine				
Assess Rwanda's existing medicine quality control systems and capacity and recommend possible improvements		<ul style="list-style-type: none"> Conducted assessment of Rwanda's QA/QC capacity Proposed work plans for PMI and PEPFAR 			
Equip and ensure repairs of NUR Faculty of Pharmacy QC lab and provide reagents needed to test antimalarial medicines		Planned for Q2		<p>Hired a local supplier to deliver all needed reagents for testing antimalarials</p> <p>As possible, repairs of the lab equipment will take place during training</p>	
Train NUR QC Lab staff, MOH-PTF pharmacists,		Planned for Q2-Q3	Procured all materials for training on HPLC, TLC, and	<ul style="list-style-type: none"> Shipped all training materials 	Activity on hold pending clearance by

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
and a local manufacturer in key QC methods			dissolution	<ul style="list-style-type: none"> – Hired a local supplier to deliver all needed reagents for the training – The training is planned for Q4. Delays were caused by difficulty in finding a local supplier for chemicals and the time needed to get them into Rwanda 	USAID/Rwanda; PQM is following up
Build capacity through QC testing of antimalarials from private and public sectors by NUR QC Lab and PQM evaluation		Planned for Q2–Q4			Activity on hold
Senegal	L. El Hadri				
Strengthen and expand national capacity for medicine quality monitoring of antimalarial, anti-TB, and antiretroviral medicine and oral contraceptives by providing equipment, supplies, and training		<ul style="list-style-type: none"> – Identified one sentinel site – Procured and delivered one Minilab – Provided supplies for MQM activities – Trained 24 staff in Minilab basic tests 	<ul style="list-style-type: none"> – Revised sentinel site report for June-December 2009 round and provided comments – Summary of this report was submitted to USAID/Senegal – FY10 round will start May 2010 – Revised the new protocol to include role of family planning and to give mandate of MQM program to DPL – QC testing for oral contraceptive is ongoing at USP lab 	<ul style="list-style-type: none"> – Sentinel site report for June-December 2009 round will be disseminated July 2010 – Budget submitted for 2010 Minilab program – USP RS delivered to LNCM – Funds to procure chemicals to LNCM provided – 4 columns will be delivered to LNCM by July 2010 – 2010 Minilab activities will be completed July 2010 – New protocol signed by relevant partners – MQM program under the supervision of DPL – QC testing for one oral contraceptive completed. The remaining testing will be completed in Q4. 	<ul style="list-style-type: none"> – Minilab activities for 2010 round completed. Confirmatory testing ongoing at NQCL – 4 new columns procured and delivered to NQCL – One electrochemical detector with training manual donated to NQCL. – QC testing of oral and injectable contraceptives, tested at USP, completed and report is under review

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Provide information, education, and communication on medicine quality through data reporting and communication campaigns		Submitted report for 2007-2008 Minilab round	<ul style="list-style-type: none"> Final report of 2008-2009 is under review Meetings held to discuss IEC activities for the upcoming communication campaign 	Report will be submitted by July 2010	<ul style="list-style-type: none"> Sentinel site report for 2009 disseminated to relevant stakeholders Agenda and budget of education and communication campaign prepared and submitted to USAID/Senegal for approval
Strengthen pharmacovigilance system			<ul style="list-style-type: none"> Pharmacovigilance action plan provided to USAID/Senegal Preparation for PV workshop is ongoing 	PV workshop agenda finalized and budget submitted. Workshop will be held July 2010	<ul style="list-style-type: none"> Pharmacovigilance workshop on boosting reporting completed. 32 staff from central and regional levels participated in the workshop
Uganda	L. El Hadri				
Provide TA on antimalarial MQM by providing M&E guidelines to improve the implementation of the protocol; review data from the previous round of sampling and testing and assist in disseminating the report				Visit is planned in Q4 to ensure the implementation of the new protocol, monitor and evaluate Minilab activities on site, and review MQM data	<ul style="list-style-type: none"> Supervisory visit and M&E of Minilab activities conducted 221 antimalarials collected, 9 failed confirmatory testing and 7 recalled by NDA Report of the previous Minilab program revised and recommendations on how to improve next round provided to NDA Report will be disseminated by NDA to relevant stakeholders
Strengthen the capacity of the NDQCL to test antimalarials		<ul style="list-style-type: none"> Procured and delivered one dissolution tester Procured one UV-vis spectrophotometer Procured one printer and computer 	<ul style="list-style-type: none"> Provided training on installation and proper use of dissolution tester Provided printer for dissolution tester Installation of UV vis spectrophotometer is pending 	Dissolution tester and UV-vis Spectrophotometer installed and training on proper use of equipment provided	

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
ASIA					
RDM-A Mekong Malaria S Phanouvong					
Obtain evidence-based data on antimalarial, selected antibiotics and HIV/AIDS medicines through a regional monitoring program					
Continue evidence-based data collection through existing medicine quality monitoring to support regulatory actions in the region	S. Phanouvong	<ul style="list-style-type: none">Laos collected and tested 232 samples (1 counterfeit)Vietnam collected and tested 38 samplesThailand collected 984 samples and tested 182 with Minilab (11 failed so far)Produced 2009 Annual Report with data summary of all countries; submitted to USAID/ RDM-AProduced report on Vietnam data 2003-2009 and submitted to USAID/ Vietnam	Laos FDD established a local team to organize the meeting Regional Efforts to Improve Medicines Quality in Southeast Asia: Accomplishments, Challenges and Future Strategies. 5,128 antimalarial samples and 3,021 antibiotics have been collected and tested by Cambodia, Laos, Thailand and Vietnam from 2005-2009.	Laos contract agreement finalized. Thailand and Vietnam to finalize MOC for continuing MQM activities with collaboration between reg authority, national QC lab, and disease programs with PQM support. (This activity is jointly funded by RDM-A TB, and AI)	Presented most recent data findings from Oct 2009-Sep 2010 at the MMP meeting in Phuket, Thailand in Sep. Vietnam MOC finalized.
Strengthen national, provincial and district health authorities to provide timely reporting and share the medicines quality data that is routinely collected for in-country enforcement and regional action against violators					
Strengthen national, provincial and district authorities for effective regulatory action and enforcement in Laos, Thailand, and Vietnam	S. Phanouvong	Completed review of relevant regulatory enforcement current practices to develop SOPs	Drafted guidance document for taking regulatory and enforcement action against poor quality medicines and collected PQM input. Presented the document at the Regional Meeting and requested country input.	<p>Incorporated comments into draft guidance document.</p> <p>Drafted 5-year strategy document on MQM (resulting from Laos regional meeting in Q2.</p> <p>Worked with Thai FDA Director of Drug Control division and BVBD Malaria Cluster, and BDN to finalize MOC for PQM-supported program, incl. MQM and taking effective action.</p> <p>Worked with Vietnam DAV, NIDQC, and NIMPE to</p>	Worked with Vietnam DAV, NIDQC, and NIMPE to finalize MOC for PQM-supported program, incl. MQM and taking effective action. (This activity is also funded by RDM-A TB).

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
				finalize MOC for PQM-supported program, incl. MQM and taking effective action. (This activity is also funded by RDM-A TB)	
Intensify collaboration and data-sharing with relevant partners in the region for collective action	S. Phanouvong	<p>Data is being compiled by country</p> <p>An online medicines quality database is being developed with USP IT and PQM staff for partners and the public to access MQM data from SE Asia.</p>	<p>At the Regional Meeting in Laos, concrete ideas were discussed regarding information sharing. A timely report on failed samples should be shared among relevant MRAs. Confirmed cases should be shared with WHO Rapid Alert System, and Interpol. PQM is creating a publicly accessible medicine quality database on the USP website which will be ready for internal review and testing by Q3.</p>	<p>Concept for regional mechanism for enforcement action among national authorities discussed at Lower Mekong Initiative conference in Vietnam.</p> <p>Received USAID clearance to collaborate with INTERPOL and other enforcement agencies on counterfeit and substandard medicines. (This activity is also funded by RDM-A TB)</p>	<p>Medicine quality database completed development with USP IT. Will perform data entry and request country authorization to make data publicly available in FY11.</p>
Raise public awareness about the dangers of counterfeit and substandard medicines					
Re-edit public service announcements (PSAs) to meet country broadcast requirements (Laos, Vietnam, and Thailand) and get PSA cleared by relevant authorities in Cambodia, Laos, Vietnam, and Thailand; finalize regional documentary, and if possible produce a new	S. Phanouvong	<ul style="list-style-type: none"> Documentary film proposal developed; budget awaiting approval from PQM. Re-edits of PSAs completed. Cambodia PSA on hold indefinitely due to political issues. Completed filming and editing <i>Combating counterfeit medicines on the frontlines in SE Asia</i> 	<ul style="list-style-type: none"> Revised proposal with budget sent to PQM for final approval. Approval for PSAs to be broadcast in Laos and Thailand given by FDD and FDA. Awaiting further funding sources to begin documentary Awaiting further review of PSAs by Vietnam DAV 	<p>Written clearance from Laos authority obtained to broadcast PSAs in Laos.</p> <p>Verbal approval given by Director of DAV contingent on contract agreement with O2 TV, which can then expand to other stations as part of a national campaign.</p> <p>Verbal approval given by the</p>	<p>No progress on follow up with Vietnam and Thailand for formal clearance to broadcast PSAs.</p> <p>Finalized contract with Soho Films on regional documentary film production</p>

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
documentary.				FDA Drug Control Division to broadcast PSA in Thailand. (This activity is also funded by RDM-A TB)	
Support outreach activities in grass-roots community organizations to raise awareness about counterfeit/fake medicines.	S. Phanouvong	No progress	In Cambodia, a project to engage local Khmer artists to create a national poster campaign is underway. Meta House has hired the artists and had initial consults.	Pharmacide Arts Project of Cambodia exhibition opened in June at Meta House Cambodia Discussion of project expansion to Laos, Vietnam, and Thailand with support by PQM, US Dept of State, French Min. of Foreign Affairs, and private donors	No progress made in Q4
Submit an article on Cambodia/Thailand cross- border antimalarial medicines quality study to a peer-reviewed journal	S. Phanouvong	Completed rough draft of abstract, introduction, and methodology of article on Thailand	Revised the draft manuscript on Thailand. Request for countries' approval to disseminate and publish data on cross-border study was submitted and approval from Thailand was obtained. Awaiting approval from Cambodia.	Drafted, in partnership with the Thai study investigators, a manuscript for final internal review on Thai results for potential publication in peer review journal. Still awaiting formal clearance from Cambodia.	Submitted a pre-submission enquiry on manuscript on Thailand side of the study to PLoS Med; it was accepted and requested for full submission; awaiting feedback from editors.
Improve PQM regional approach and activity implementation through program review and information sharing with key stakeholders					
Organize a regional meeting of key partners in GMS countries to share medicines quality data; discuss lessons learned; revise sampling techniques as needed; and report recommendations for effective regional cooperation to combat SCMs	S. Phanouvong	Meeting is scheduled for March in Vientiane, Laos	Completed. A meeting was held March 29-31, with 55 representatives. A document on improving MQM in the region was drafted.	Disseminated trip report from meeting including drafts of "5-year strategy for GMS MQM program" and "Guidance on Enforcement" for country partners PQM regional activities presented in 'counterfeit and substandard medicines' session at the Lower Mekong Initiative meeting with partners, chaired by Admiral T. Ziemer of PMI. (This activity is also funded by	Incorporated comments and finalized the Guide on Enforcement Action and re-disseminated the document to countries in SE Asia. Presented the regional strategies for MQM in GMS at MMP meeting and incorporated key areas in the RDM-A malaria and TB work plans.

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
				RDM-A TB, OPHT and AI)	
Provide technical assistance to ensure the quality of all antimalarial medicines to be used in RDM-A funded clinical trials in the Mekong Subregion					
Collect and test antimalarial samples from study investigators or suppliers before (and 8 months thereafter) they are introduced to the USAID/RDM- A supported clinical trials	S. Phanouvong	Collected and completed tests of 4 antimalarials (artemether and artesunate) from Cambodia's western border to support URC's efficacy trials in malaria containment zone in Cambodia	Requested by Clinton Foundation in Cambodia to test ACTs (artemisinin + piperquine) made by Holley Pharmaceuticals. These will be widely distributed near the Cambodia-Thai border. Communicating with Clinton how/when this can be carried out.	Identify antimalarial products of priority for analytical method development: DHA/PIP; and Atovaquone/Proguanil to be jointly developed by ANEQAM/Chulalongkorn Univ/NIDQC and PQM Consultant.	No requests were sent to PQM for testing.
Strengthen PQM technical leadership and collaboration with partners in the region through hiring new staff and south-south collaboration					
Recruit a lab technical consultant, based in the Mekong Sub-region to work closely with the existing Regional Consultant in Southeast Asia	S. Phanouvong	Job advertisements placed in Thailand; of 30 applicants, 3 were shortlisted	Held phone interviews with 3 candidates. One candidate selected for in person interview in Thailand and Laos. Decision to be made in early Q3	Asawin Likhitsup, PhD, was selected and has been working since May. His office and lab space will be located at partner institution Chulalongkorn Univ. in Bangkok. (This activity is also funded by RDM-A TB, OPHT and AI)	Technical consultant actively involved in implementing PQM activities; has traveled to Vietnam and the Philippines.
Support the Vietnam NIDQC in providing technical assistance to Laos National QC Lab (FDQCC) towards ISO 17025 accreditation	S. Phanouvong	Held Initial discussions	Arranged a visit to FDQCC by a NIDQC representative who participated in the Regional Meeting March 29-31 to lay out plans for assistance, including a visit of two QA personnel from NIDQC in June	NIDQC and FDQCC are working on a detailed action plan for TA. NIDQC to send experts to FDQCC in August to determine specific activities to be performed and guide FDQCC to compile necessary dossiers required by ISO. (This activity is jointly funded by RDM-A TB)	No progress made with this activity due to a request from Laos FDQCC that NIDQC should delay sending its experts to Laos in Q4 because the MOHs of Laos and Vietnam are holding a high level meeting to discuss bilateral cooperation in QA/QC system strengthening; and the quality manual of FDQCC is not yet fully translated into English for the experts to review.
Review and improve drug quality indicators for pharmacies to ensure the quality of medicines during the process of acquisition, storage, and handling					
Review most suitable pharmaceutical guidance documents, develop	S. Phanouvong	Collected selected WHO materials to review for adapting and developing	Reviewed selected WHO materials and Laos Pharmacy "10 Indicators	No progress	No progress made due to other priorities; the activity is postponed to of FY11.

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
consolidated platform with indicators to ensure appropriate attention to medicines quality assurance		appropriate platform and indicators	to evaluate retail pharmacy practice for ensuring the quality of medicines to be procured, stored, and dispensed."		
RDM-A Tuberculosis S. Phanouvong					
Obtain data on anti-tuberculosis medicines through a regional monitoring program					
Continue evidence-based data collection through existing medicine quality monitoring to support regulatory actions in the region	S. Phanouvong	8 ATB samples collected and tested in Laos, 5 in Vietnam	625 TB samples were collected and tested from 2005-2009. The results were examined and discussed at the Laos regional meeting.	Laos contract agreement finalized. Thailand and Vietnam to finalize MOC for continuing MQM activities with collaboration between reg authority, national QC lab, and disease programs with PQM support	Presented most recent data findings from Oct 2009-Sep 2010 at the MMP meeting in Phuket. Vietnam MOC finalized.
Organize a regional Training-of-Trainers on new Minilab methods for second-line ATBs for participants from Cambodia, Laos, Thailand, and Vietnam	S. Phanouvong	Completed training materials of relevant second-line ATBs (levofloxacin, moxifloxacin, and prothionamide); training scheduled for Q2 or Q3	Initial communication and discussion took place in Laos (during the regional meeting) with Thai and Vietnamese partners to hold this workshop. Awaiting decision.	Training completed at the NIDQC in Hanoi, Vietnam for 11 participants from Laos, Vietnam, Cambodia, and Thailand on new Minilab methods for 2 nd -line TB medicines (Levofloxacin, Moxifloxacin and Prothionamide)	Activity completed in Q3.
Support country trainers to conduct a national training workshop for their sentinel site personnel	S. Phanouvong		Discussed with Thai and Vietnamese partners as above	Budget proposals created following training in Hanoi, countries to submit proposals for training workshops in Q4	National training workshops will be completed in FY11 for all countries (Cambodia and Vietnam in Q1; Laos and Thailand in Q2)
Strengthen national, provincial and district authorities to provide timely reporting and share the medicines quality data that is routinely collected for in-country enforcement and regional action against violators					
Strengthen national, provincial and district authorities for effective regulatory action and enforcement in Laos, Thailand, and Vietnam	S. Phanouvong	Completed review of relevant regulatory enforcement current practices to develop SOPs	Drafted guidance document for taking regulatory and enforcement action against poor quality medicines and collected PQM input. Presented the document at the Regional Meeting and requested country input.	Incorporated comments into draft guidance document. Drafted 5-year strategy document on MQM (resulting from Laos regional meeting in Q20 Worked with Thai FDA Director of Drug Control	Worked with Vietnam DAV, NIDQC, and NIMPE to finalize MOC for PQM-supported program, incl. MQM and taking effective action. (This activity is also funded by RDM-A Malaria).

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
				<p>division and BVBD Malaria Cluster, and BDN to finalize MOC for PQM-supported program, incl. MQM and taking effective action.</p> <p>Worked with Vietnam DAV, NIDQC, and NIMPE to finalize MOC for PQM-supported program, incl. MQM and taking effective action. (This activity is also funded by RDM-A TB)</p>	
Intensify collaboration and data-sharing with relevant partners in the region for collective action	S. Phanouvong	Data is being compiled by country	<p>At the Regional Meeting in Laos, concrete ideas were discussed regarding information sharing. A timely report on failed samples should be shared among relevant MRAs. Confirmed cases should be shared with WHO Rapid Alert System, and Interpol. PQM is creating a publicly accessible medicine quality database on the USP website which will be ready for internal review and testing by Q3.</p>	<p>Concept for regional mechanism for enforcement action among national authorities discusses at Lower Mekong Initiative conference in Vietnam.</p> <p>Received USAID clearance to collaborate with INTERPOL and other enforcement agencies on counterfeit and substandard medicines</p>	Medicine quality database completed development. Will perform data entry and request country authorization to make data publicly available in FY11.
Raise public awareness about the dangers of counterfeit and substandard medicines					
Re-edit PSAs to meet the country broadcast requirements (Laos, Cambodia, and Vietnam) and get clearance from relevant in-country authorities; finalize regional documentary	S. Phanouvong	<ul style="list-style-type: none"> Documentary film proposal developed; budget awaiting approval from PQM. Re-edits of PSAs completed. Cambodia PSA on hold indefinitely due to political issues. Completed filming and 	<ul style="list-style-type: none"> Revised proposal with budget sent to PQM for final approval. Approval for PSAs to be broadcast in Laos and Thailand given by FDD and FDA. Awaiting further funding sources to begin 	<p>Written clearance from Laos authority obtained to broadcast PSAs in Laos.</p> <p>Verbal approval given by Director of DAV Vietnam contingent on contract agreement with O2 TV, which can then expand to other</p>	<p>No progress on follow up with Vietnam and Thailand for formal clearance to broadcast PSAs.</p> <p>Finalized contract with Soho Films on regional documentary film production</p>

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
		editing <i>Combating counterfeit medicines on the frontlines in SE Asia</i>	documentary -Awaiting further review of PSAs by Vietnam DAV	stations as part of a national campaign. Verbal approval given by the FDA Drug Control Division to broadcast PSA in Thailand. (This activity is also funded by RDM-A Malaria, OPHT)	
Support outreach activities in grass-roots community organizations to raise awareness about counterfeit medicines	S. Phanouvong	No progress	In Cambodia, a project to engage local Khmer artists to create a national poster campaign is underway. Meta House has hired the artists and had initial consults.	Pharmacide Arts Project of Cambodia exhibition opened in June at Meta House Cambodia Discussion of project expansion to Laos, Vietnam, and Thailand with support by PQM, US Dept of State, and French Min. of Foreign Affairs, and private donors. (This activity is also funded by RDM-A Malaria)	No progress made in Q4
Improve PQM regional approach and activity implementation through program review and information sharing with key stakeholders					
Organize a regional meeting of key partners in GMS countries to share medicines quality data; discuss lessons learned; revise sampling techniques as needed; and report recommendations for effective regional cooperation to combat SCMs	S. Phanouvong	Meeting scheduled for March in Vientiane, Laos	Completed. A meeting was held March 29-31, with 55 representatives. A document on improving MQM in the region was drafted.	Disseminated trip report from meeting included drafts of "5-year Strategy for GMS MQM Program" and "Guidance on Enforcement" for country partners PQM regional activities presented in 'counterfeit and substandard medicines' session at the Lower Mekong Initiative meeting with partners, chaired by Admiral T. Ziemer of PMI (This activity is also funded by RDM-A Malaria, OPHT and AI)	Incorporated comments and finalized the Guide on Enforcement Action and re-disseminated the document to countries in SE Asia. Presented the regional strategies for MQM in GMS at MMP meeting and incorporated key areas in the RDM-A malaria and TB work plans.
Strengthen PQM technical leadership and collaboration with partners in the region through hiring new staff and south-south collaboration					
Recruit a lab technical	S.	Job advertisements placed	Held phone interviews	Asawin Likhitsup, PhD, was	Technical consultant actively

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
consultant, based in the Mekong Sub-region to work closely with the existing Regional Consultant in Southeast Asia	Phanouvong	in Thailand; of 30 applicants, 3 were shortlisted	with 3 candidates. One candidate selected for in-person interviews in Thailand and Laos. Decision will be made in early Q3.	selected and has been working since May. His office and lab space will be located at partner institution Chulalongkorn Univ. in Bangkok. (This activity is also funded by RDM-A TB, OPHT and AI)	involved in implementing PQM activities; has traveled to Vietnam and the Philippines.
Support the Vietnam NIDQC in providing technical assistance to Laos National QC Lab (FDQCC) towards ISO 17025 accreditation	S. Phanouvong	Began initial discussions	Arranged a visit to FDQCC by a NIDQC representative who participated in the Regional Meeting March 29-31 to lay out plans for assistance, including a visit of two QA personnel from NIDQC in June	NIDQC and FDQCC are working on a detailed action plan for TA. NIDQC to send experts to FDQCC in August to determine specific activities to be perform and guide FDQCC to compile necessary dossiers required by ISO. (This activity is also funded by RDM-A Malaria)	No progress made with this activity due to a request from Laos FDQCC that NIDQC should delay sending its experts to Laos in Q4 because the MOHs of Laos and Vietnam are holding a high level meeting to discuss bilateral cooperation in QA/QC system strengthening; and the quality manual of FDQCC is not yet fully translated into English for the experts to review.
Develop drug quality indicators for pharmacies to ensure the quality of medicines during the process of acquisition, storage, and handling					
Review most suitable pharmaceutical guidance document to ensure appropriate emphasis on medicine quality assurance indicators for pharmacies to guide proper acquisition, storage, and sale of good quality medicines	S. Phanouvong		Reviewed selected WHO materials and Laos Pharmacy “10 Indicators to evaluate retail pharmacy practice for ensuring the quality of medicines to be procured, stored and dispensed.”	No progress	No progress made due to other priorities; the activity is postponed to FY11 Q2.
RDM-A Other Public Health Threats		S. Phanouvong			
Utilize ANEQAM’s technical expertise to support GMS countries in manufacturing, inspection, quality control, and dossier evaluation for drug registration					
Mahidol University’s Faculty of Pharmacy will conduct 2 follow-up GMP trainings on-site in Cambodia and Laos building upon the needs	L. Krech	Awaiting final approval of RDM-A work plan to approach Mahidol about proposed activities in Q3-Q4	RDM-A work plan approved, initial discussions have begun.	Following a meeting with Mahidol Faculty of Pharmacy Dean and professors, 2 experts from Mahidol will conduct GMP on-site visits to Laos and Cambodia in Q4	This has been postponed until FY11 Q1-Q2.

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
and requests from these countries during a joint training at Mahidol in August 2009.					
Chulalongkorn University will perform a 3-day training on advanced compendial analyses of oseltamivir for participants from Thailand, Laos, Vietnam, and Cambodia.	L. Krech	Awaiting final approval of RDM-A work plan to meet with Chulalongkorn about proposed activities in Q3-Q4	RDM-A work plan approved. Activity plan sent to Chulalongkorn; awaiting their response.	Due to political instability in Bangkok, the training was carried out at the NIDQC in Hanoi by PQM, Chula, and NIDQC. 11 participants from 4 countries were trained. This training was carried out jointly with the Minilab training on 2 nd line tuberculosis medicines (see RDM-A TB activities): 3 days on compendial testing of oseltamivir and 2 days on Minilab testing of second-line TB medicines.	Activity completed in Q3.
Re-engage UST CeDRES as an ANEQAM partner	L. Krech	Will communicate with CeDRES in Q2-Q3.	No progress	No progress.	No progress.
Contribute to the costs of organizing the Regional Meeting on Medicines Quality, and strengthening PQM program leadership and collaboration in the region					
Contribute to the cost of organizing a Regional meeting to review and share medicine quality data and lessons learned (as described in Malaria Obj. 4/1 and TB Obj. 4/1 funding earlier)	S. Phanouvong	Began meeting planning of meeting scheduled for March in Vientiane, Laos	Meeting completed	Disseminated trip report from meeting including drafts of "5-year Strategy for GMS MQM Program" and "Guidance on Enforcement" for country partners PQM regional activities presented in 'counterfeit and substandard medicines' session at the Lower Mekong Initiative meeting with partners, chaired by Admiral T. Ziemer of PMI (This activity is also funded by RDM-A Malaria, TB and AI)	Incorporated comments and finalized the Guide on Enforcement Action and re-disseminated the document to countries in SE Asia. Presented the regional strategies for MQM in GMS at MMP meeting and incorporated key areas in the RDM-A malaria and TB work plans.
Contribute to the salary cost of the Technical	S. Phanouvong	Scheduled short-listed candidates for telephone	Held phone interviews with 3 candidates. One	Asawin Likhitsup, PhD, was selected and has been	Technical consultant actively involved in implementing

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Consultant		interviews	candidate selected for in-person interviews in Thailand and Laos. Decision will be made in early Q3.	working since May. His office and lab space will be located at partner institution Chulalongkorn Univ. in Bangkok. (This activity is also funded by RDM-A TB, OPHT and AI)	PQM activities; has traveled to Vietnam and the Philippines.
Contribute to support of Laos FDQCC toward ISO accreditation	S. Phanouvong	Began Initial discussions	Arranged a visit to FDQCC by a NIDQC representative who participated in the Regional Meeting March 29-31 to lay out plans for assistance, including a visit of two QA personnel from NIDQC in June	NIDQC and FDQCC are working on a detailed action plan for TA. NIDQC to send experts to FDQCC in August to determine specific activities to be performed and guide FDQCC to compile necessary dossiers required by ISO. (This activity is also funded by RDM-A Malaria, and TB)	No progress made with this activity due to a request from Laos FDQCC that NIDQC should delay sending its experts to Laos in Q4 because the MOHs of Laos and Vietnam are holding a high level meeting to discuss bilateral cooperation in QA/QC system strengthening; and the quality manual of FDQCC is not yet fully translated into English for the experts to review.
RDM-A Avian Influenza					
Strengthen the quality control systems of MRAs in the GMS and monitor AI product quality.					
Continue evidence-based data collection through existing medicine quality monitoring to support regulatory actions in the region	C. Raymond	No oseltamivir collected during MQM in Q1	Will begin collecting in Thailand in Q3.	Delays in contract finalizing have postponed this activity to Q4 in Thailand and Vietnam. Approval for sampling and testing oseltamivir from stockpiles was given in Thailand (BVBD) and in Vietnam (with NIDQC and DAV)	Per request from Cambodia health authority, samples from the Central Medical Stores were collected and analyzed at NIDQC. All samples passed quality specifications. Report was sent to the Cambodia authority*.
Establish a mechanism to support regulatory decisions and communication regarding extension of AI products shelf-life	C. Raymond	Contacted two Deputy Ministers of Health of Vietnam to provide oseltamivir TA	BVBD agreed to do pilot study on oseltamivir. Short protocol training course to be held in Q3; will begin collecting samples after	DAV and NIDQC of Vietnam agreed to allow TA from PQM to implement protocol of sampling and testing following meetings in June BVBD will sample and test	Formal clearance received for sampling and testing stocks in Thailand (DDC) and Vietnam (DAV, NIDQC, NIMPE) for pilot study*.

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Provide technical assistance to ASEAN to test quality and monitor stockpiled AI products in Singapore and/or at any other regional warehouses	C. Raymond	Offered assistance to ASEAN secretariat; will follow up in Q2	Teleconference with ASEAN secretariat scheduled for Q3.	following MOC No progress in Q3	No progress in Q4*. * PQM regional coordinator made a presentation on AI program achievements at the AI end-of-program meeting in Bangkok in August 2010.
Cambodia					
Improve detection of poor-quality medicines circulating in the Cambodian market.					
Support existing post-marketing surveillance program, together with the Department of Drugs and Food (DDF), the Global Fund (GFATM) and the National Health Product Quality Control Center (NHPQ)	L. Krech	<ul style="list-style-type: none"> Inter-Ministerial Committee to Eliminate Counterfeit Medicines and Illegal Health Services met to discuss actions taken in the provinces PQM drafted a report for release in Q2 	IMC end-of-year report distributed. Drafted joint press release (PQM and Cambodian MOH) to be released in Q3 on drop in illegal outlets. Sampling and testing of antimalarials and antibiotics continues in collaboration with the Global Fund. Local consultant has visited 4 of the 12 sentinel sites.	<ul style="list-style-type: none"> Joint press release (PQM and Cambodian MoH) was issued on action taken to close down illegal pharmacy outlets. PQM Director and Consultant visited Cambodia and met with PQM partners to strengthen partnership. Cambodia DDF/MoH drafted a new protocol and workplan for sampling and testing in Cambodia. MoC between PQM and MoH is signed 	Local consultant traveled to 6 sentinel sites to examine how local staff are conducting postmarketing surveillance. Report written summarizing site visits.
Strengthen the NHPQ	L. Krech	TA assessment of the NHPQ lab facility and site and blueprints for future lab facility will be conducted in Q2-Q3.		<ul style="list-style-type: none"> Comment on NHQC Blueprint sent to NHQC Director to discuss with MoH and Architect Company to make necessary modification 2 NHQC staff attended training on compendial testing of Oseltamivir and Minilab testing of TB medicines held in Hanoi 	<p>Continued communication on NHQC blueprints.</p> <p>Implementation plan to reach ISO 17025 and/or WHO Prequalification will be created in FY11.</p>

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Hire and train new PQM local consultant	L. Krech	<ul style="list-style-type: none"> – Consultant hired and being trained – Consultant attended meetings on behalf of PQM in Cambodia 	Consultant has been trained on basic testing techniques and attended PV, Malaria Task Force, and WHO QA/QC protocol meetings, among others. Consultant coordinated communication between NHPQ and DDF to produce the 5-year country report and poster for the Regional Meeting in Laos.	Consultant attended training on compendial testing of Oseltamivir and Minilab testing of TB medicines held in Hanoi	Local consultant met with local partners to update them on PQM activities and also to explore joint collaboration in FY11.
Expand and improve pharmacovigilance in Cambodia					
Continue to operationalize the Cambodian Pharmacovigilance Center (CPC)	L. Krech	PQM, the Cambodian MOH, WHO, and the Cambodian Pharmacovigilance Center worked with a healthcare communications consultant from Uppsala Monitoring Center to conduct a one-day pharmacovigilance strengthening meeting.	PQM has completed all planned PV activities for the fiscal year. PQM follows the development of the CPC, work plans with AMFm, and PV activities directed towards ACTs.	Due to staff changes, this activity is on hold. AMFm will take on most of the PV activities	Activity is on hold indefinitely.
Raise awareness about medicine quality issues and disseminate information among regulators, health care professionals, and the public					
Produce and distribute regional documentary film on counterfeit medicines	L. Krech	Film proposal, sequence list completed; awaiting budget approval	Budget finalized and approved; revised proposal submitted for final review	Proposal finalized and pre-production completed with indication of additional funding from WIPO. Production to begin in Cambodia and Laos in Q4	Finalized contract with Soho Films on regional documentary film production
Collaborate with the Pharmacists' Association of Cambodia (PAC) on activities to promote actions against counterfeit and substandard medicines	L. Krech	One workshop completed on 1) Use of capillary electrophoresis for the quality control of Drugs (Mr. Ing Ho, pharmacist, Geneva, Switzerland); and 2) Development process from molecule to marketing of finished medicinal	Planned for Q3 and Q4	<ul style="list-style-type: none"> – Workshop on Accredited Pharmacy and Good Pharmacy Practice held; another workshop is planned for Q4 – Newsletter is being prepared by PAC 	Workshops and newsletters are planned for FY11

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
		products (Yimeng Lune, Geneva, Switzerland)			
Philippines					
Ensure continued postmarketing surveillance of tuberculosis medicines at the 6 pilot sites and examine status of project implementation.					
Trained CHD and LGU staff will perform testing and sampling according to the Department Order protocol PQM will monitor sampling and testing at selected sentinel sites, and provide technical assistance/training as necessary	L. Krech	Drafted end-of-the-calendar-year report on TB MQM activities which will be released to USAID Mission in Q2	Report distributed. Consultant has performed site visits to reinforce basic testing techniques and correct reporting of results.	Consultant resigned and PQM, with the help of the Philippines FDA, is currently looking for a new consultant. Previous consultant is still assisting PQM to implement activities	PQM staff interviewed candidates and hired a new consultant. PQM examined the data from all sites at the stakeholders meeting in July 2010 (see activity below). Comments/changes were made to the MQM protocol based upon data and feedback from sentinel site staff.
PQM will visit two sites in FY10 together with FDA/DOH staff	L. Krech	Site visits planned for Q3-Q4	Site visits planned for Q3-Q4	Site visits planned for Q4.	PQM staff not able to perform site visits; this activity is planned for FY11 when new SE Asia program manager is hired.
Organize a meeting in Manila to: (1) examine pilot site TB data and actions taken over the past 1-1/2 years; (2) discuss successes and challenges of pilot program; (3) through shared decision-making, come to a conclusion regarding how DOH-FDA-NTP can continue the MQM project when USAID funding ends and the roles of each institution; and, (4) discuss if and how TB medicine quality monitoring can be integrated with FDA-in-a-	L. Krech	Planned for Q3-Q4	Planned for Q3-Q4	Meeting planned for Q4 for 28 attendees (3 staff members from each of the 6 sentinel sites, FDA, and PQM)	Meeting held. MQM protocol is being adapted from feedback received during the meeting. New modules (on rules and regulations of FDA, waste management and disposal, and overview of national TB Control program) will be added to future training.

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
suitcase/Quality Basket initiative.					
Support the Project Secretariat to coordinate, purchase necessary supplies and equipment, and report progress on postmarketing surveillance of TB medicines and other PQM-supported activities in the Philippines	L. Krech	Consultant visited Davao and participated in an FDA yearly strategic meeting; report will be ready in Q2	Consultant continues to purchase necessary supplies, communicate with the six sentinel sites, and report progress to PQM headquarters.	Consultant resigned in Q3, however until June she purchased necessary supplies and continues to communicate with the six sentinel sites and report progress to PQM headquarters (until a new consultant is hired).	PQM staff interviewed candidates and hired a new consultant.
Participate in the Mekong Regional Meeting on medicines quality and share findings with the region and partners	L. Krech	This will occur in Q2	3 Philippines representatives participated in the Regional meeting and created a country presentation, report, and poster.	Completed in Q2	Completed in Q2.
Strengthen FDA and satellite laboratories					
Perform a comprehensive assessment of the FDA and how the new government laws to strengthen the FDA are impacting quality assurance regulatory actions	L. Krech	Planned for Q3	Planned for Q3	Planned for Q4	Assessment document drafted and will be circulated to Philippines FDA in FY11.
Building on GLP training conducted in FY09, invite 2 FDA staff to become visiting scientists at USP Headquarters	L. Krech	<ul style="list-style-type: none"> – FDA selected two scientists – Schedule will be designed and approved by USP in Q2 	10 week schedule has been designed. Visiting scientists will arrive at USP headquarters the beginning of Q4.	Visiting Scientists to arrive in Q4.	Visiting scientists arrived at end of Q4 for 10 week visit.
USP QA and PQM staffs continue to review documents FDA submits to the PAO to identify gaps and provide recommendations	L. Krech	PAO performed an on-site assessment of the microbiology lab; FDA will share results with PQM in Q2	FDA provided PAO assessment results of 3 laboratories. PQM staff reviewed and provided recommendations. PQM is using this information to maximize the experience of the visiting	PQM drafted a press release on the FDA's success in attaining ISO 17025 accreditation; will be circulated Q4. Visiting scientists will have time to train with QA to explore areas for improvement for the	Visiting scientists began designing an implementation plan with PQM staff to help the FDA laboratories maintain ISO accreditation.

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
			scientists.	Philippines FDA laboratories.	
Collaborate with FDA, EU* and WHO on the FDA Quality Basket initiative *Technical Assistance for Health Sector Policy Support Program in the Philippines/EU Funded Programme managed by the DOH and EC.					
FDA, WHO, and PQM will conduct a training for 16 regions on sampling and testing 16 essential medicines using protocols and similar equipment currently in use for TB quality monitoring	L. Krech	FDA trained 8 regions on only 4 essential medicines in November; PQM staff did not attend due to other commitments but plan to attend training planned for February/March	No other training performed this quarter. FDA will inform PQM when the next training is scheduled.	No other training has been scheduled by the FDA at this point. More information will be obtained in Q4.	Training will be carried out in FY11.
Europe and Eurasia					
Russia					
Conduct trainings for laboratory staff from Roszdravnadzor's national network of drug quality control and, possibly, for selected manufacturers of second line TB medicines in quality control of pharmaceuticals	K. Burimski	<ul style="list-style-type: none"> – Developed and sent to Roszdravnadzor the list of courses that could be conducted for its staff – Selected a Roszdravnadzor scientist to participate in USP Visiting Scientist program at USP Headquarters 	<ul style="list-style-type: none"> – Developed and sent to Roszdravnadzor the preliminary program of courses that could be conducted for its staff and secured approval from Roszdravnadzor – Selected USP facilitators to provide the course – Began preparing materials for the course – Prepared visit of Roszdravnadzor scientist to USP Headquarters 	<p>Eight training courses were developed, tailored to suit the needs of the RZN staff, and translated into Russian. The trainings were held in May for 98 participants representing five regional/federal district labs, the Scientific Centre laboratory, and one medicine manufacturer from Kazakhstan. In a letter to USP Executive Director Roger Williams, Dr. E. A. Telnova, Acting Director of Roszdravnadzor, expressed appreciation to USP for preparing the trainings and conveyed their wish to collaborate in the future.</p> <p>Dr. Andrey Korolev, a scientist at Roszdravnadzor's Scientific Center of Expertise of Medical Products who was selected by USP to participate in its Visiting Scientist program, started the</p>	<ul style="list-style-type: none"> – Disseminated course materials to interested parties – Dr. Andrey Korolev completed USP visiting scientist program

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
				internship, working on dissolution-related project.	
Conduct an internship at USP HQ for Russian GMP experts with focus on WHO prequalification Requirements; Develop support capacity for second-line TB medicines TA in Russia by training qualified Russian scientists who would help with follow-ups and translation requirements	K. Burimski	<ul style="list-style-type: none"> – Discussed internship with Roszdravnadzor and Drug Safety Research Institute – Began selection of interns 	Continued cooperation with Roszdravnadzor and Drug Safety Research Institute in selecting interns	Continued selection of specialists from Roszdravnadzor laboratories and manufacturers for internship	<ul style="list-style-type: none"> – Four candidates from Roszdravnadzor expressed interest in participating in the internship; two were selected – Due to Sep 1 reorganization of Roszdravnadzor and Russian Ministry of Health and Social Development, the candidates are no longer Roszdravnadzor employees; they report to MOH – Drafted a letter to MOH seeking approval for the candidates to participate in the internship
Conduct a Symposium on WHO prequalification for Russian 2nd line TB medicine manufacturers	K. Burimski	<ul style="list-style-type: none"> – Developed program for the symposium – Identified co-chairs and key speakers – Secured approval and support from Roszdravnadzor – Roszdravnadzor agreed to provide a list and contact information of Russian manufacturers of second-line TB medicines 	<ul style="list-style-type: none"> – Finalized the symposium program and list of invitees based on USAID/Russia suggestions – Sent invitation letters to manufacturers, Roszdravnadzor, Drug Safety Research Institute, etc. 	The symposium was held at the Man & Drugs Conference in Moscow in April. At least 40 people attended and 14 firms from Russia, Ukraine, and Belarus were represented	
Provide technical assistance to manufacturers of second line TB medicines on WHO prequalification	K. Burimski	<ul style="list-style-type: none"> – Secured Roszdravnadzor approval and support – Roszdravnadzor agreed to provide a list and 	Compiled a list, including contact information, of Russian manufacturers of second-line TB medicines and disseminated the list to	<ul style="list-style-type: none"> – Continued reviewing Dossiers from Sintez on Levofloxacin 500mg tablets and Kanamycin powder for injection; sent 	<ul style="list-style-type: none"> – Facilitated visit of GDF specialist to Sintez – Sintez submitted dossiers on Kanamycin 0.5 and 1.0 powder for

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
		contact information of Russian manufacturers of second line TB medicines	interested parties	<p>comments to Sintez to implement correctives actions</p> <ul style="list-style-type: none"> Translated Expression of Interest Questionnaire for SLD manufacturers into Russian and disseminated it to selected Russian and Ukrainian SLD manufacturers 	<p>injection to WHO</p> <ul style="list-style-type: none"> WHO did not accept the dossiers and requested additional information to be submitted by December 7, 2010 Updated <i>Expression of Interest Questionnaire for SLD manufacturers</i> and continued disseminating it to Russian and Ukrainian SLD manufacturers
Disseminate results of the study "Assessing the Impact of the <i>Infectious Diseases Textbook</i> & the Distance Education Courses on Prescribing Patterns of Antimicrobial Medicines in Selected Health Facilities in Russia"	K. Burimski	Submitted report of study to PQM for editing	Prepared and sent draft version of final report for comment	<ul style="list-style-type: none"> Continued reviewing the report addressing comments from interested parties Discussed further steps of dissemination with interested parties 	Results of the study were presented as a poster at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston in September 2010
Conduct training courses on basic tests using Minilabs; document and report medicines quality data and provide recommendations	K. Burimski	<ul style="list-style-type: none"> Identified training participants and venue Began translating training materials into Russian Prepared draft of training program 	<ul style="list-style-type: none"> Received Minilabs Finalized program of the training course Translated training materials into Russian Purchased necessary chemicals and other supplies for the training 	<p>The training was held in Moscow April 5-9 and was attended by eight specialists, of whom six were from three TB clinics and two represented the QC lab of Roszdravnadzor.</p> <p>Received a letter from Acting Director of Roszdravnadzor, which conveyed their wish to continue the Minilab project</p>	Drafted and discussed with partners Memorandum of Collaboration on MQM between PQM and the TB clinics
Latin America and the Caribbean					
Amazon Malaria Initiative (AMI) V. Prihluda					
Evaluate and support accessibility and quality of malaria diagnosis and treatment facilities					
Strengthen QA systems and incorporate the three-level approach to ensure the quality of		<ul style="list-style-type: none"> Received and reviewed first draft of Manual of Procedures for the Management of Malaria 	Final draft of the of Manual of Procedures for the Management of Malaria Medicines and associated	Contributed to AMI Strategic Orientation Document for 2011-2015. Developed section on Quality Assurance	Discussions on incorporating the Three Level Approach into country QA plans are on-

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
medicines throughout the supply chain, particularly in low transmission settings		<p>Medicines (MPMMM) and related SOPs from Guyana.</p> <ul style="list-style-type: none"> – Reviewed version sent on January 2010 – Received final draft of the MPMMM and associated SOPs from Colombia; currently under review 	<p>SOPs from Colombia was reviewed and returned with comments and recommendations</p>	<p>of Malaria Medicines in High and Low Incidence Conditions</p>	<p>going with several AMI countries</p>
Establish sustainable south-south collaborations among OMCLs in AMI countries; follow up on FY09 workshop		<ul style="list-style-type: none"> – Provided Reference Standards for 8 countries (Bolivia, Brazil, Colombia, Ecuador, Guatemala, Guyana, Jamaica and Panama) to participate in the latest round of inter-laboratory proficiency testing sponsored by Peru OMCL (CNCC) – Six countries delivered results (Bolivia, Brazil, Colombia, Guyana, Jamaica & Panama) for three tests; 16/18 (89%) test results from AMI participating countries evaluated by CNCC as satisfactory – Sponsored two analysts Ecuador OMCL to participate in training on Biological and Microbiological Assays for Pharmaceutical Products sponsored and delivered by Peru's OMCL (CNCC); PAHO sponsored two analysts from El Salvador OMCL 	<ul style="list-style-type: none"> – Assisted CNCC in coordinating inter-laboratory proficiency testing rounds for 2010. There will be two rounds in 2010 and currently, 9 and 11 labs will participate in the 1st and 2nd round respectively. – The OMCL Virtual Forum Project Charter was drafted which describes the purpose, mission, and scope of the project. The document is in its final review before being forwarded to in- country partners. 	<ul style="list-style-type: none"> – Sent RS to 9 labs (and coordinated for USP and PAHO to include a 10th lab – Uruguay's OMCL) for first round in 2010. – CNCC will send results of round in Q4. Sponsored CNCC personnel participation in QMS evaluation of Panama OMCL (see below under Support OMCLs to implement stringent Quality Management Systems) – Developed User Requirements Document for OMCL Virtual Forum to be submitted to an external consultant; currently under review by IT 	<ul style="list-style-type: none"> – First round of 2010 inter-laboratory proficiency testing sponsored by Peru OMCL (CNCC) finalized, with the participation of Bolivia, Brazil, Colombia, Jamaica, Panama, Peru and Costa Rica – Sponsored two CNCC staff to visit Guatemala OMCL to assess implementation of the Corrective and Preventive Actions (CAPA) developed after PQM assessment in Nov 2009. – Consultant for development of OMCL Virtual Forum identified and development work initiated <ul style="list-style-type: none"> o Virtual Forum expected to be finalized Oct/Nov 2010
Strengthen MRAs' GMP			PQM and PAHO's HSS/MT	Letter of Intent for	Contacts established with

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
inspection capabilities, specifically for local antimalarial medicine manufacturers			<p>team met to finalize institutional agreement to proceed with PQM activities aimed at strengthening MoH regulatory capabilities.</p> <ul style="list-style-type: none"> – PQM developed draft of letter of intent and sent to PAHO for review – Final version finalized incorporating PAHO's suggestions. 	<p>collaboration on strengthening MoH regulatory capabilities sent to PAHO in April</p> <ul style="list-style-type: none"> – Letter is still under review and no update has been provided – Due to the lack of response from PAHO, PQM contacted the Latin America office of FDA to develop a joint PQM/FDA training – FDA LA Office agreed and is currently assessing how to implement it 	<p>the FDA LA Office to start coordination of this activity; will be delivered in FY11</p>
Expand Colombia's capacity to perform QC analysis of medicines by strengthening the National Network of Laboratories			<p>PQM was requested to attend a meeting in May to promote the establishment of a National Network of Laboratories, organized by INVIMA. No final date has been established for this meeting</p>	<ul style="list-style-type: none"> – Meeting date has been set for end of August – In consultation with the NMCP, two Departmental Health Laboratories were identified to receive Minilabs in order to support the implementation of the three-level approach in routine MQM 	<ul style="list-style-type: none"> – Attended First Workshop of the National Network of Laboratories organized by Colombia MRA (INVIMA). <ul style="list-style-type: none"> o The use of Basic Tests and the Three-level approach for Quality Control was introduced and discussed with the representatives from the Departmental Secretaries of Health, and will be implemented by network laboratories. – Provided technical guidance to the agency in Colombia that will procure Minilab sponsored by the Global fund
Assist in antimalarial		– Received medicines	– Continued analysis at	See below under 'Conduct	– Received Minilab results

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Medicine Quality Monitoring (MQM) activities		<p>sampled in private and informal sector of Suriname; currently being analyzed at USP Lab</p> <ul style="list-style-type: none"> – Ordered and sent Minilab supplies to Suriname NMCP analytical lab – Reviewed report of MQM Minilab activities in Colombia; comments and recommendations sent back to NMCP 	<p>USP of the samples received from Suriname & Guyana</p> <ul style="list-style-type: none"> – PQM met with Suriname NMCP representatives at the AMI/RAVREDA meeting in Bolivia regarding samples remaining in country – Waiting for approval from Suriname MoH to send remaining samples for analysis at USP HQ. – Provided Ecuador NMCP with RS to perform routine MQM in public sector 	<p>study of QC of antimalarials at informal sites'</p> <ul style="list-style-type: none"> – Suriname MoH approved shipment of remaining samples that were sent to PQM for analysis at USP lab – Provided Ecuador NMCP with Minilab manuals in Spanish to perform routine MQM in public sector 	<p>of medicines sampled during FY10 in:</p> <ul style="list-style-type: none"> ○ Colombia. 59 samples. All passed. ○ Bolivia: 24 samples. All passed ○ Results do not include confirmatory testing by OMCL – Ordered and sent reference standards for Minilabs in Peru
Support OMCLs to implement stringent Quality Management Systems (QMS) to comply with internationally recognized standards (WHO and/or ISO)		<ul style="list-style-type: none"> – Performed of Quality Management System (QMS) Assessment at Guatemala OMCL – Provided support to LNS for preparing Expression of Interest (Eol) to participate in WHO PQ Programme 	<ul style="list-style-type: none"> – See comment under SAIDI CONCAMYT & CNCC sections 	<ul style="list-style-type: none"> – Performed Quality Management System (QMS) Evaluation at Panama OMCL. Assessment performed in collaboration with personnel from CNCC (Peru OMCL). Interaction between Peru and Panama OMCLs has been continuous as Peru has provided TA for a variety of QC procedures, particularly microbiological methods – Assisted Bolivia & Peru OMCLs in developing Corrective and Preventive Action Report that was submitted to WHO Prequalification team. Awaiting final decision from WHO regarding including both labs in list of PQ labs. (See under 	<ul style="list-style-type: none"> – CNCC (Peru OMCL) added to the list of WHO prequalified labs for: <ul style="list-style-type: none"> ○ Physical/ Chemical analysis ○ Identification ○ Assays, impurities and related substances ○ Microbiological tests – CONCAMYT (Bolivia OMCL) added to the list of WHO prequalified labs for: <ul style="list-style-type: none"> ○ Physical/ Chemical analysis ○ Identification ○ Assays, impurities and related substances – See also Guatemala (above under Establish sustainable south-south collaborations) – Visiting Scientist

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
				SAIDI) – Sponsored translation of revised WHO GLPs into Spanish. Document will be harmonized and approved by the PANDRH GLP WG Meeting in Peru in July (PQM will attend meeting) – Visiting Scientist Program <ul style="list-style-type: none"> Coordinated activities with USP personnel involved in training and logistics Information submitted to process the visa of the scientist that will be participating from the Caribbean Regional Drug Testing Laboratory in Jamaica. – Created with PAHO a joint work plan for OMCL activities performed by PQM, PAHO, & USP.	Program <ul style="list-style-type: none"> Completed all logistics for the training at USP and visa requirements for the representative from the Caribbean Regional Drug Testing Laboratory in Jamaica. Training will begin in Oct 2010. – Attended the 7th Meeting of the PANDRH GLP Working Group. The main objective was to harmonize and make official the Spanish translation of the newly published WHO Good Practices for National Pharmaceutical Control Laboratories. Note: PQM provided the translation, which was subsequently edited and approved. The document has been distributed to the region's OMCLs and will be printed by PAHO.
Strengthen pharmacovigilance (PV) activities in selected countries		See comment below	See comment under cGMP section	Letter of Intent for collaboration on strengthening MoH regulatory capabilities sent to PAHO in April <ul style="list-style-type: none"> Letter is still under review in PAHO and no update has been provided (See also Q2 comment under	This activity will not be pursued.

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
Establish a LAC secondary standard program		Exploring potential approaches with PAHO for USP assistance and alternative approaches	<p>PQM is evaluating the possibility of having OMCLs buy RS directly from USP at a reduced price. The objective is to increase the availability and reduce the cost of all USP RS.</p> <ul style="list-style-type: none"> To determine if this approach is feasible, PQM is compiling information from OMCLs in the region regarding the use and cost of the RS used. Additionally, PQM is compiling information regarding the logistical process of having OMCLs purchase RS directly from USP at a reduced price. 	<p>cGMP)</p> <p>USP developed alternative approaches to strengthen this program in several regions of the world and support to the countries will not be managed through PQM. Further information will be discussed with region as it becomes available.</p>	Activity on hold pending USP consideration of a new initiative regarding reference standards
<p>Conduct GMP assessment of Farmanguinhos; verify AS/MQ FDC quality</p> <p>(carry over from DQI)</p>			<ul style="list-style-type: none"> PQM reiterated to Farmanguinhos the intent of the GMP assessment and proposed to assist in PQ Process of this FDC. PQM is waiting final decision from Farmanguinhos regarding proposal. Since carry over funds need to be utilized by the end of FY 10, if by the end of Apr/May Farmanguinhos does not respond to PQM or an action plan cannot be coordinated with them to complete this activity during FY 10, this activity will be 	<p>Due to changes in the infrastructure of the factory and the manufacturing process, pre-qualification plans and TA by PQM have been postponed for 2011, until the validation of systems and processes in the manufacturing plant are completed</p>	<p>Farmanguinhos submitted the dossier for WHO prequalification of AS/MQ FDC and requested PQM to perform a GMP evaluation of their facility by FY11 Q2, in preparation for WHO audit.</p>

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
			discontinued and the funding reallocated.		
<p>Conduct study of QC of antimalarials at informal sites in locations with high prevalence of illegal commerce of medicines in Colombia, Guyana, and Suriname</p> <p>(covered in part by carry over from DQI)</p>		<ul style="list-style-type: none"> – All medicines sampled from the private and informal market in Guyana received and are currently being analyzed at USP and CNCC – Signed contract for study on medicines from the private and informal market in Colombia with country consultant (COHAN); study to start in January 2010 – See comment #1 in MQM activities (re: Suriname) 	<ul style="list-style-type: none"> – Continued to analyze medicines from Guyana at USP and CNCC. Final results expected in Q3. – Study on the availability of antimalarials in the private and informal sector of three departments in Colombia has been initiated – See comments #1, 2 & 3 in MQM activities (re: Suriname) 	<ul style="list-style-type: none"> – Continued analysis at USP of the samples received from Suriname & Guyana – CNCC completed 19 of 29 samples from Guyana – Remaining samples at CNCC delayed because of inability of local suppliers to deliver reagents. PQM is working with CNCC to find alternative suppliers. – Analysis at USP lab of samples received from Guyana and Suriname at final stages of completion 	<ul style="list-style-type: none"> – Analysis of samples from Guyana: <ul style="list-style-type: none"> ○ Finalized at USP lab ○ Supplier to deliver reagents to complete analysis of remaining samples at CNCC. Reagents will be delivered FY11 Q1 – Analysis of samples from Suriname: <ul style="list-style-type: none"> ○ All samples are from the same medicine (Artecom) ○ Analysis of the first shipment has been completed ○ Analysis of second shipment is being evaluated in order not to repeat analysis of the same lots assessed for Guyana – Colombia: Study on the availability of antimalarials in the private and informal sector of three departments with high incidence of malaria has been completed. Draft of final report received and reviewed. Comments and request for additional information sent to contractor
Train health professionals of all levels in the diagnosis, appropriate management, and use of antimalarials					
Write an article with		– Drafted article outline	Began drafting	An early draft of completed	Refinement of early draft

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
results of Minilab activities at sentinel sites (mostly public sector); submit to peer-reviewed journal		– Reviewing MQM data received since inception of program; additional related information being requested from countries	introduction section and analyzing basic tests (Minilab) data from Bolivia, Colombia, Ecuador, Guyana and Suriname	sections is under review	in progress.
Write an article with results of case studies in Colombia, Guyana, and Suriname on the quality of malaria medicines at the private and informal sectors					Completion of the analyses of most samples from Guyana and Suriname and of the assessment in Colombia will initiate the writing of this article
Finalize concept paper on use of the Three-level approach for quality control of medicines in developing countries		Final draft finalized and is currently under internal review	Further revisions are being made to the draft and the final document is expected to be ready in Q3	Final draft of revised version has been completed and is currently under review by PQM team	Comments received from PQM team and incorporated into final draft. Article will be finalized and disseminated FY11 Q1/Q2
Develop an online database of information on the quality of antimalarial medicines in AMI countries. (IT development funded by USP)		<ul style="list-style-type: none"> – Finalized and approved user requirements document – IT programmers began constructing site; estimated completion Q3 	<ul style="list-style-type: none"> – PQM and USP IT Department continued developing the database – Completion expected on Q3 	<ul style="list-style-type: none"> – Development of the database software has been completed by IT, and assessed by PQM – Public access to database expected by mid-Q1 FY11 <ul style="list-style-type: none"> o Uploading of existing data is expected to be finalized throughout the next two quarters 	<ul style="list-style-type: none"> – Began search for temporary consultant to support the upload of data – Discussions and presentation of database with countries health authorities initiated in order to get approval for public dissemination of data – Launch expected FY11 Q2
Promote and implement evidence-based decisions on accessibility, quality, and use of appropriate diagnosis and treatment					
Participate in the annual, steering committee, and other regional meetings with initiative countries and technical partners			Attended IX Annual AMI/RAVREDA and semi-annual steering committee meetings in Santa Cruz, Bolivia		Attended AMI Steering Committee Meeting in Washington, D.C.
Maternal and Child Health V. Pribluda					
Assess the quality of selected obstetric and neonatal medicines used in primary care health facilities in decentralized regions of Peru and Guatemala					
Develop study protocol		– Identified partners and relevant stakeholders in	Peru: – Protocol refined with	Peru: – Protocol finalized	Guatemala: – Approval received from

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
		Guatemala and Peru; project objectives presented and discussed – Debriefed USAID/ Guatemala on project – Currently developing protocol for Peru (to be shared with country partners in Q2)	in-country partners and includes sites and medicines to sample. – Sampling is scheduled to be performed simultaneously with SAIDI study in two stages (2 regions in May and 3 remaining regions in June) Guatemala: – Proposal for Study to be presented to the MoH – Proposal developed by PQM is currently under review by in-country partners – Expected submission date to MoH: May 2010 Upon approval PQM will hire an in-country consultant to perform sampling and send samples to PQM designated lab.	Guatemala: – Proposal completed and sent to in-country partners for submission to MoH in April – A change in senior decision-making officials in the MoH and a national emergency delayed submission of the proposal to the end of Q3. Response expected in July. – Terms of Reference for consultant sent to in-country partners.	the MoH – Site for sampling selected (Santa Rosa Department) – Consultant hired – Protocol under development – Sampling expected during Nov/Dec 2010
Conduct sampling and QC testing				Peru: – Sampling completed in all regions and medicines sent to CNCC – USP Reference Standards sent to CNCC – Results expected by Q4	Peru: – 147 samples sent to CNCC – Medicines currently under analysis at CNCC – Additional reagents were requested to complete analysis and will be shipped Oct 2010 – Completion of analysis expected Nov 2010
Prepare and disseminate					

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
report					
South American Infectious Diseases Initiative (SAIDI) A. Barojas					
Increase breadth of evidence base for LAC PHN priorities increased regionally.					
Coordinate and institutionalize sampling and analysis of selected medicines (ABs, TB & NSAIDs) in Bolivia & Peru		<ul style="list-style-type: none"> – Provided a 1-day course to UNIMED (Bolivia's MRA) on Appropriate Use of USP-NF standards – Peru—third round temporarily put on hold until MCH protocol is finalized – Both MCH and SAIDI activities will be performed in the same region for efficient use of resources 	Peru: Third round protocol finalized; sampling will occur concurrently with MCH study to maximize funds. Sampling will occur in two stages (2 regions in May and 3 remaining regions in June).	Peru: <ul style="list-style-type: none"> – Sampling finalized in all regions and medicines sent to CNCC – USP Reference Standards sent to CNCC – Results expected by Q4 	Peru: <ul style="list-style-type: none"> – 257 samples sent to CNCC (includes 58 Non-steroidal anti-inflammatory drugs) – Medicines currently under analysis at CNCC – Completion of analysis expected during FY11 Q1
Cross-cutting activities related to QA/QC (to be implemented dependent on further developments) in Peru, Ecuador & Paraguay	PQM/DQI	Provided input to Links Media and other SAIDI partners on draft 'SAIDI Approach' document on expansion of SAIDI into Ecuador; Links Media finalizing draft	<ul style="list-style-type: none"> – 'SAIDI Approach' document is still pending approval by USAID. – PQM has received approval from USAID to assist Ecuador National TB Control Program (NTBCP) in MQM of common AB & TB medicines stored in decentralized public health centers. – PQM will provide RS to perform routine MQM 	– 'SAIDI Approach' document is still pending approval by USAID.	<ul style="list-style-type: none"> – 'SAIDI Approach' document presented by Links Media at SAIDI Steering Committee (SC) for comments <ul style="list-style-type: none"> o PQM LAC Team reviewed and sent comments – As a result of limited funding to SAIDI, the SC decided that during FY11 will focus resources to apply this approach. with an emphasis on AMR for TB, in another region in Peru <ul style="list-style-type: none"> o Identification of new region is currently being evaluated by PAHO and SPS
Communicate and use evidence base for LAC PHN priorities.					
All participating countries collect, analyze, disseminate and evaluate information					
Assist CONCAMYT (Bolivia) to establish a			– Visited CONCAMYT to assist them in	– Assisted Bolivia OMCL in developing Corrective and	CONCAMYT added to list of WHO prequalified labs. See

PQM Activity	Staff Lead	Quarter			
		Q1	Q2	Q3	Q4
stringent QMS to comply with international standards (WHO & ISO) (carry over from DQI)			preparing for the WHO Inspection – WHO PQ Programme Inspection Conducted March 22-23 (Final report is pending)	Preventive Action Report that was submitted to WHO Prequalification team. Awaiting final decision from WHO regarding inclusion of CONCAMYT to list of PQ labs.	above under 'Support OMCLs to implement stringent Quality Management Systems' in AMI
Assist CNCC (Peru) to obtain WHO prequalification & expansion of ISO 17025 accreditation		<ul style="list-style-type: none"> – Provided support to CNCC on EoI to participate in WHO PQ Programme – CNCC's EoI sent in October; WHO Headquarters accepted EoI Schedule of WHO audit TBD 	<ul style="list-style-type: none"> – CNCC expanded ISO 17025 scope to include 7 more tests. ACLASS audit conducted March 8-12 and final report pending. As a result 90% of work performed by lab is accredited and recognized internationally. – WHO PQ Programme Inspection Conducted March 25-26 (Final report is pending) 	<ul style="list-style-type: none"> – ACLASS approved CNCC's expanded scope and the lab is now currently accredited for 12 tests, which comprises approximately 90% of work performed by lab. – Assisted Peru OMCLs in developing Corrective and Preventive Action Report that was submitted to WHO Prequalification team. Awaiting final decision from WHO regarding inclusion of CONCAMYT to list of PQ labs. 	CNCC added to list of WHO prequalified labs. See above under 'Support OMCLs to implement stringent Quality Management Systems' in AMI
Promote more inclusive and better informed policy process. All participating countries define and implement policies in conjunction with participation of all sectors, including the community					
Publish article on MQM activities performed in all SAIDI countries		In progress	In progress	In progress	
Participate in all SAIDI meetings					Attended SAIDI Steering Committee Meeting